CMECs exert a direct positive effect on cardiomyocyte contraction and relaxation, which is mainly mediated by endothelial-derived NO. Pro-inflammatory stimulation of CMECs by pre-incubation with TNF-a or interleukin-1b abrogates the positive regulatory function of these cells on cardiomyocyte contractile property. Mechanistically, pro-inflammatory activation of CMECs leads to mitochondrial and cytoplasmic ROS accumulation that results in the scavenging of NO. Empagliflozin directly restores the beneficial effect of CMECs on cardiomyocyte contraction and relaxation by reducing TNF-a-induced mitochondrial and cytoplasmic ROS accumulation, which leads to reinstatement of CMEC-derived NO delivery.
SUMMARY
The positive findings of the EMPA-REG OUTCOME trial (Randomized, Placebo-Controlled Cardiovascular Outcome Trial of Empagliflozin) on heart failure (HF) outcome in patients with type 2 diabetes mellitus suggest a direct effect of empagliflozin on the heart. These patients frequently have HF with preserved ejection fraction (HFpEF), in which a metabolic risk-related pro-inflammatory state induces cardiac microvascular endothelial cell (CMEC) dysfunction with subsequent cardiomyocyte (CM) contractility impairment. This study showed that CMECs confer a direct positive effect on contraction and relaxation of CMs, an effect that requires nitric oxide, is diminished after CMEC stimulation with tumor necrosis factor-a, and is restored by empagliflozin. Our findings on the effect of empagliflozin on CMEC-mediated preservation of CM function suggests that empagliflozin can be used to treat the cardiac mechanical implications of microvascular dysfunction in HFpEF. Therapies that are used in HF patients with reduced EF (HFrEF) have failed to improve primary outcomes in patients with HFpEF (2) (3) (4) (5) , which suggests different pathomechanisms in HFpEF compared with HFrEF. Recently, the paradigm of HFpEF has shifted from a mere cardiomyocyte (CM) disease to a disorder that initially involves cardiac microvascular endothelial cells (CMECs), which subsequently leads to CM dysfunction (6, 7) . Comorbidities, such as type 2 diabetes mellitus (DM), obesity, hypertension, and chronic kidney disease, are highly prevalent in patients with HFpEF (8) (9) (10) . These metabolic diseases are accompanied by microvascular endothelial dysfunction, including that of CMECs, which are characterized by impaired nitric oxide (NO) generation, increased reactive oxygen species (ROS) production, inflammatory activation (7, (11) (12) (13) , and rarefaction of the cardiac microvascular bed (14) .
Recent findings in patients with breast cancer showed that the relative risk of HFpEF increased with increasing cardiac radiation exposure during breast cancer radiotherapy (15, 16) . In adults, CMs do not or rarely proliferate and thus are highly radioresistant (17) (18) (19) . Cardiac radiation exposure causes coronary microvascular endothelial cell (EC) damage and inflammation with subsequent coronary microvascular dysfunction and rarefaction that impair myocardial function (19) (20) (21) . These studies provide proof of concept as they underpin the essential role of the cardiac microvascular endothelium in determining risk of left ventricular (LV) diastolic dysfunction. Interaction between endocardial ECs and CMs has been shown in earlier studies on cardiac papillary muscles (22, 23) . However, a direct causal effect of cardiac microvascular endothelial dysfunction on cardiac contraction and relaxation, which has been proposed based on clinical associations (11, 24) , needs to be fundamentally established. If the CMEC-CM axis plays an important role in the pathogenesis of HFpEF, improvement of CMEC function may represent an important target in developing new treatments and prevention strategies for HFpEF.
Empagliflozin, a sodium glucose transporter 2 (SGLT2) inhibitor that is primarily used in patients with type 2 DM to lower blood glucose levels, may represent a novel therapy to treat HFpEF patients.
Recent findings of the EMPA-REG OUTCOME trial (Randomized, Placebo-Controlled Cardiovascular Outcome Trial of Empagliflozin) showed an unexpected beneficial effect of empagliflozin on HF outcome in patients with DM and suggested that empagliflozin acts not only on kidney tubular cells but also directly on the heart (25) . The significant reduction of cardiovascular mortality and HF hospitalization by empagliflozin treatment (19, 25) The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors' Juni et al. Adult rat CMs were isolated using liberase digestion of hearts as described previously (29, 30 Figure 1 ) and subsequently measured the contraction and relaxation kinetics of individual CMs paced at 2 Hz (Figure 1) . The presence of CMECs significantly enhanced CM contraction as shown by an increase in the fractional shortening or the proportion of sarcomere length shortening (Figures 2A and 2D) .
CMECs also improved CM relaxation as indicated by a higher relaxation velocity (Figures 2B and 2E) Figures 4A and 4B) , which increased by exposure to acetylcholine ( Figures 4A and 4B) . In contrast, exposure of CMECs to TNF-a largely reduced the NO Effect of Empagliflozin on Endothelial CellÀCardiomyocyte Interaction S E P T E M B E R 2 0 1 9 : 5 7 5 -9 1 bioavailability to a level nearly similar to that in the presence of L-NAME ( Figures 4A and 4B ). Empagliflozin has been reported to directly affect CMs (27) . We also observed that 1 mM empagliflozin treatment of CMs enhanced CM function (Supplemental Figures 6A and 6D) and relaxation (Supplemental Figures 6B, 6C , 6E, and 6F), which indicated that empagliflozin could directly act on CMs and regulate their contractile profile.
However, this direct effect did not explain the results of the co-culture experiments because empagliflozin was only present in the CMEC compartment during the 6 h pre-treatment period and was removed before the onset of co-culture with CMs.
To underscore the effect of empagliflozin on NO production in CMECs, we determined the cellular NO concentration in CMECs. Live-cell microscopy evaluation showed that NO levels in CMECs were reduced by exposure of the cells to TNF-a but was maintained when the cells were incubated with TNF-a and empagliflozin simultaneously ( Figures 7A and 7B ). Figure 8A) . Empagliflozin neither affected the amount of eNOS dimer nor altered the eNOS monomer content in control or TNF-a-exposed CMECs (Supplemental Figure 8A ). Furthermore, after Effect of Empagliflozin on Endothelial CellÀCardiomyocyte Interaction S E P T E M B E R 2 0 1 9 : 5 7 5 -9 1 rescued NO bioavailability, which was diminished by exposure to TNF-a (Supplemental Figure 8C ). The induction of ROS production by TNF-a was fully blunted by co-treatment with empagliflozin ( Figures 7E and 7F) . We then examined whether the reduction of ROS with empagliflozin co-treatment was due to a direct antioxidant or radical scavenging capacity of empagliflozin. Using DPPH as a free radical, we observed that empagliflozin at 1 and 10 mM concentration showed no direct antioxidant capability, whereas the antioxidants butylated hydroxytoluene and ascorbic acid displayed a strong direct radical scavenging effect ( Figure 7G) .
TNF-aÀinduced ROS generation is complex and
involves various pathways, resulting in ROS generation, as well as modulation of ROS scavenging enzymes. TNF-a can induce ROS production via NOX4 (31, 34) . However, we observed no effects of empagliflozin on NADPH oxidase 4 (NOX4) expression (Supplemental Figure 7E ). In addition, empagliflozin did not alter the mRNA expression of the radical scavenging enzymes SOD1 and SOD2 after TNF-a stimulation (Supplemental Figures 7C and 7F) . NOX1, NOX2, NOX3, NOX5, and SOD3 mRNA in CMECs remained below detection level in these conditions (data not shown).
Mitochondria are a major source of ROS (31) . JNK activation is enhanced by TNF-a and can contribute to mitochondrial ROS production (31) . However, the TNF-a-induced JNK phosphorylation was not altered by empagliflozin (Supplemental Figure 8D ). However, we observed that TNF-a induced mitochondrial ROS generation in CMECs ( Figures 7H and 7I) , and remarkably, empagliflozin significantly reduced the mitochondrial ROS production that was enhanced by TNF-a exposure ( Figures 7H and 7I) . Overall, because empagliflozin showed no direct antioxidant capacity, these data suggested that, in the presence of TNF-a stimulation, empagliflozin could activate intracellular mechanisms that cause a reduction in mitochondrial ROS generation. This resulted in an inhibition of cytoplasmic ROS accumulation, which led to an enhancement of CMEC NO bioavailability.
DISCUSSION
In a co-culture model of CMECs and CMs, we showed leukin-1b. This is of interest for the pathogenesis of HF because Paulus and Tschöpe (7) and others (14, 16) proposed that inflammatory activation of CMECs might be a pivotal initial mechanism in changing the cardiac mechanical properties in HFpEF. Using an NO copper-based probe with high sensitivity for detecting NO at minute levels (39, 40) , we confirmed that expo- Second, TNF-a reduces NO by its ability to enhance ROS generation (44, 45) , potentially either via an im- Effect of Empagliflozin on Endothelial CellÀCardiomyocyte Interaction
